Suppr超能文献

相似文献

1
Transparency in Decision Modelling: What, Why, Who and How?
Pharmacoeconomics. 2019 Nov;37(11):1355-1369. doi: 10.1007/s40273-019-00819-z.
2
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250.
4
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
5
Best-worst scaling to assess the most important barriers and facilitators for the use of health technology assessment in Austria.
Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):223-232. doi: 10.1080/14737167.2017.1375407. Epub 2017 Sep 8.
6
Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results.
Pharmacoeconomics. 2024 Jul;42(7):783-795. doi: 10.1007/s40273-024-01374-y. Epub 2024 Apr 12.
7
Transparency in Health Economic Modeling: Options, Issues and Potential Solutions.
Pharmacoeconomics. 2019 Nov;37(11):1349-1354. doi: 10.1007/s40273-019-00842-0.
9
Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158. doi: 10.3310/hta8360.
10
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood.
Pharmacoeconomics. 2019 Nov;37(11):1305-1312. doi: 10.1007/s40273-019-00825-1.

引用本文的文献

2
The PHEM-B toolbox of methods for incorporating the influences on Behaviour into Public Health Economic Models.
BMC Public Health. 2024 Oct 12;24(1):2794. doi: 10.1186/s12889-024-20225-1.
3
Paving the path for implementation of clinical genomic sequencing globally: Are we ready?
Health Aff Sch. 2024 Apr 29;2(5):qxae053. doi: 10.1093/haschl/qxae053. eCollection 2024 May.
4
A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening.
Appl Health Econ Health Policy. 2024 Jul;22(4):527-542. doi: 10.1007/s40258-024-00887-z. Epub 2024 May 16.
5
A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations.
Pharmacoeconomics. 2024 Jul;42(7):797-810. doi: 10.1007/s40273-024-01376-w. Epub 2024 Apr 13.
6
Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results.
Pharmacoeconomics. 2024 Jul;42(7):783-795. doi: 10.1007/s40273-024-01374-y. Epub 2024 Apr 12.
7
Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network.
Pharmacoeconomics. 2022 Oct;40(10):1005-1009. doi: 10.1007/s40273-022-01179-x. Epub 2022 Jul 30.
8
Four Aspects Affecting Health Economic Decision Models and Their Validation.
Pharmacoeconomics. 2022 Mar;40(3):241-248. doi: 10.1007/s40273-021-01110-w. Epub 2021 Dec 16.
9
Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time.
Pharmacoeconomics. 2022 Mar;40(3):249-256. doi: 10.1007/s40273-021-01116-4. Epub 2021 Dec 6.
10
Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom.
Value Health. 2020 Nov;23(11):1432-1437. doi: 10.1016/j.jval.2020.07.001. Epub 2020 Aug 27.

本文引用的文献

1
A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis.
Pharmacoeconomics. 2019 Jun;37(6):829-843. doi: 10.1007/s40273-018-00765-2.
2
Check Your Checklist: The Danger of Over- and Underestimating the Quality of Economic Evaluations.
Pharmacoecon Open. 2019 Dec;3(4):433-435. doi: 10.1007/s41669-019-0118-3.
3
Development and Validation of the Evaluation Platform in COPD (EPIC): A Population-Based Outcomes Model of COPD for Canada.
Med Decis Making. 2019 Feb;39(2):152-167. doi: 10.1177/0272989X18824098. Epub 2019 Jan 24.
4
Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge.
Value Health. 2018 Jun;21(6):724-731. doi: 10.1016/j.jval.2018.02.002. Epub 2018 Apr 9.
5
Model Registration: A Call to Action.
Pharmacoecon Open. 2017 Jun;1(2):73-77. doi: 10.1007/s41669-017-0019-2.
6
Statistical Code to Support the Scientific Story.
Ann Intern Med. 2018 Jun 5;168(11):828-829. doi: 10.7326/M17-3431. Epub 2018 Feb 6.
7
Ahead of Our Time: Collaboration in Modeling Then and Now.
Pharmacoeconomics. 2017 Sep;35(9):975-976. doi: 10.1007/s40273-017-0532-2.
8
Data-Sharing Models.
N Engl J Med. 2017 Jun 8;376(23):2305. doi: 10.1056/NEJMc1705477.
9
Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling.
Pharmacoeconomics. 2017 Aug;35(8):755-757. doi: 10.1007/s40273-017-0516-2.
10
Advantages of a Truly Open-Access Data-Sharing Model.
N Engl J Med. 2017 Mar 23;376(12):1178-1181. doi: 10.1056/NEJMsb1702054.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验